11th RWE, Market Access, Pricing & Reimbursement

Defining Value to Obtain Informed Evidence Optimizing Patient Access to Medicines

  • 00Days
  • 00Hours
  • 00Minutes
  • 00Seconds

Available Shortly!

KEY INDUSTRY EXPERT SPEAKERS

Meet Our Professionals

Jason M. Noto

Senior Vice President, US Market Access

AVEO Oncology

Danielle Bargo

Director, RWE & US HEOR Lead

Eisai US

EUGEAN JIWANMALL

Senior Research Analyst for Medical Policy & Technology Evaluation, Independence Blue Cross

Independence Blue Cross

Available Shortly

Senior Representative

Red Nucleus

Eric Boldy

Senior Representative

Available Shortly

Eric Boldy

Senior Representative

Available Shortly

Eric Boldy

Senior Representative

Available Shortly

Eric Boldy

Senior Representative

Available Shortly

Eric Boldy

Senior Representative

Available Shortly

Eric Boldy

Senior Representative

Available Shortly

Eric Boldy

Senior Representative

Available Shortly

Eric Boldy

Senior Representative

Available Shortly

INTRODUCTION

11th RWE, Market Access, Pricing & Reimbursement 2024 Americas  

On a global scale, the pharmaceutical market is expected to grow in the years to come regardless of a recent slowdown in key markets across the globe. The increase is exacerbated by the growing and ageing population in key markets. Aside from this, increasing access to Pharmaceuticals to poor and middle-class families due to increases in disposable income also drives the industry’s growth. Pharma companies focusing on Rare and speciality medicines is another aspect leading the growth. Innovations attracting investments even from non-pharma companies are also sustaining the growth in the pharmaceutical industry.

The pharmaceutical industry is one of the major players in the healthcare sector. Payers want to provide access and fund innovative treatments to improve patient care but governments across the globe are struggling to balance the desire to provide timely access to innovative medicines with the need to contain healthcare spending due to the increasing pressure between the demands of the EU, US, national
governments and regional authorities.

RWE is playing an increasingly critical role in supporting every aspect of successful evidence-generation programs and presents immense possibilities, it also brings substantial challenges that continue to cast shadows on its validity. Concerns such as data viases, data quality, and the possible false results due to data mining, progress have diminished primarily.

The upcoming 2024 RWE, Market Access, Pricing and Reimbursement World Congress Americas will present a dynamic approach to key trends and insights on market access, health technology assessment, real-world data, patient access, pricing and reimbursement on the current European landscape.

This year, we are putting together an agenda that addresses “Defining Value to Obtain Informed Evidence Optimizing Patient Access to Medicines”. We are gathering together high caliber expert speakers to participate and share their knowledge and expertise through Keynote Presentations and Panel discussions, addressing all aspects of the industry.

We look forward to welcoming you to the RWE, MAPR 2024 congress!

Gain insights on:

  • Take part in meaningful discussions with industry experts and key decision-makers on current trends and best practices
  • Realise the potential of RWE to achieve launch success and optimal market access
  • Acknowledge the importance of RWD and RWE not only to better understand the patient populations using their drugs and the respective outcomes, but also to accelerate clinical decision support.
  • Learn from your peers about pricing and reimbursement systems in their market
  • Know how to implement a successful market access strategy and how to communicate value to stakeholders
  • Recognise the importance of innovative real-world evidence partnerships for better data
  • Hear an overview of the market access system in place in large pharma markets
  • Gain knowledge of the Market Access environment in Europe’s major markets
  • Find out the role of emerging markets Challenges and opportunities in pricing, reimbursement and patient access
  • Global and European MA trends, collaboration and spillovers
  • Payer & industry perspective for better access
  • Patient-centred approach for better outcome
  • Recognize the regulatory and clinical development framework that made an RWE- enabled development strategy attractive
  • Learn how to apply successful use cases, real-world examples, and practical outcomes into your own company or organization
  • Network with like-minded professionals to deliberate on best strategies, practices and lessons learned

Who Should Attend

Network with members of the boards, VP’s, Directors, Heads/Chiefs and Senior Managers of leading biopharmaceutical and biotech companies, government, CRO and solution providers involved in:

  • Real-World Evidence
  • Real-World Data
  • Clinical Research and Development
  • Data Science, Technologies and Analytics
  • Clinical Research
  • Epidemiology
  • Health Economics and Outcomes Research
  • Market Access
  • Reimbursement
  • Patient Outcomes
  • Drug Pricing
  • Health Economics and Outcomes Research
  • Payer Relations/ Evidence
  • Regulatory Affairs, Policy
  • Public/ Government Affairs
  • Payers, HTA Officials and Physicians
  • Business Development
  • Marketing
  • Commercial Executives
  • Product Launch
  • Commercialization
  • Value Strategy
  • Product Strategy
  • Forecaster
  • Finance Officer
  • Wearable Sensors
  • Electronic &
  • Medical Records
  • Lab & Biomarkers
  • Medical and Pharmacy data
  • Technology Science and Development
  • Social Media
  • Academia
  • Pharma and Biotech 

The program

11th RWE, Market Access, Pricing & Reimbursement 2024 Americas

Defining Value to Obtain Informed Evidence Optimizing Patient Access to Medicines

Day 1 - Monday 9th September 2024

TRENDS & STRATEGIES

  • Trends that will continue to impact, Market Access, Pricing and Reimbursement in healthcare
  • Unlocking data from early access
  • Effective communications with internal and external stakeholders
  • Embracing the digital vision
  • Future trends and developments in the healthcare distribution
  • Keeping on top of pricing and market access trends
  • Identify a clinical or economic advantage and generate the appropriate clinical and health
    economic evidence to support a strong value proposition
  • The importance of Patient-Reported Outcomes
  • Unlocking data from early access
  • Effective communications with internal and external stakeholders
  • Embracing the digital vision
  • Understanding the intricate regulatory landscape
  • Navigating complex requirements to achieve and maintain market access in the US and around the world
  • Practical approaches and strategic planning
  • Best practices
  • Benefits of understanding differences across stakeholders
  • Multiple stakeholder approach to planning and delivering evidence is required
    A dedicated strategy to meet their specific evidence needs
    Determine whether a multiple stakeholder approach is justified.
  • New landscape for risk-sharing agreements among manufacturer, payer and patients
  • Understand the benefits of a good collaboration between payers and pharma companies to ensure patient access
  • What do the decision-makers on drug usage think today about how the industry is responding to the immense challenges it is facing?
  • Addressing the factors that made the launch environment more challenging
  • Capabilities needed for an effective drug launch
  • How to best leverage outsourced partners to achieve success.
  • Best practices to achieve successful commercialisation.

REAL-WORLD EVIDENCE

  • Recent advances in digital and advanced analytics for RWE generation
  • What role can it play across the pharma value chain?
  • What are the important aspects involved in utilising RWE to support product effectiveness?
  • How can this be used to advance reimbursement model?
  • Major factors contributing to the pharmaceutical industry’s excitement about RWE
  • Addressing the challenges of collecting and consolidating RWD data that can be put to good use.
  • Important role of RWE clinical trials
  • Real-world data and evidence as a more integral part of the drug development process.

Jason Noto, Senior Vice President, US Market Access, AVEO Oncology

  • How is RWD and RWE bringing innovation to patients and gaining approval
  • Importance of RWD in transforming clinical research and clinical trial design
  • Experiences to date and identify practical and technological considerations to further implement real-world clinical research
  • The use of RWD early in the process to boost trial diversity and inclusion
  • Challenge in setting diversity goals early in clinical trial planning
  • Development of a diversity plan to ensure adequate representation of racial and ethnic
    subgroups in clinical trials
  • Utilizing RWE in the post-marketing setting to complement clinical trial findings and support post-marketing requirements or commitments for safety and efficacy data in a diverse patient population
  • Why is RWE increasingly being recognised and acknowledged as an evolution in product research and development.
  • How does RWE help regulators, pharmaceutical companies and clinicians better identify trends and patterns in patient outcomes
  • Understanding the risks & opportunities to both payer and industry
  • How does real-world evidence help ensure market access?
  • It’s use in supporting a robust post market surveillance and accelerating products to market

11th Market Access, Pricing & Reimbursement 2024 Americas

Defining Value to Obtain Informed Evidence Optimizing Patient Access to Medicines

Day 2 - Tuesday 10th September 2024

CHALLENGES & OPPORTUNITIES

  • Advantages of market access teams in payer relationship
  • Payer evidence requirement in early development
  • Best practices to obtain better pricing and reimbursement
  • Strategies to improve a better payer relationship
  • Understanding and including the patients’ perspectives in designing clinical trials and clinical endpoint
  • Key principles that ensure access to treatment based on need
  • Patient-centeredness, patient advocacy
  • Access to innovative medicines remains a key issue worldwide
  • Limitations of the some of the initiatives to address this
  • How can pharmaceutical companies and health authorities work together to bridge the gap
  • How the pharmaceutical industry will need to navigate the potential access challenges in the
  • US associated with the Inflation Reduction Act and Medicare having the authority to negotiate drug prices
  • Summary of CMS’s proposed approach to measuring value and determining a maximum fair price
  • Highlight innovative policy options that CMS should consider for robust Medicare drug price negotiations
  • Lessons learned from negotiating drug prices with governments outside of the US.

Danielle Bargo, Director, Real World Evidence and HEOR, Eisai

  • Why is this important?
  • Current state of play
  • Barriers to Equity Pricing
  • Potential solutions and some principles to maximize impact of Equity Pricing

  • Effective communications with internal and external stakeholders
  • Importance of stakeholder collaboration
  • Understanding the benefits of a good collaboration between payers and pharma to ensure appropriate patient access
  • Challenges in drug pricing and reimbursement
  • How to navigate a complex balance between financial and strategic risks
  • Strategies to offset regulatory and inflationary pressures.
  • Addressing environmental, social, and corporate governance issues
  • Encouraging cross-functional or cross-company collaborations
  • The increasing relevance of Emerging Markets
  • EMs Embrace Technological Innovation
  • Creating value through partnership
  • How to Avoid the Pitfalls of Innovation in Emerging Markets
  • Objective: Activating the full stakeholder ecosystem to shift conversation from price to value to get access to innovative therapies
  • Why is the full stakeholder ecosystem important for gaining access in the future?
  • How to Identify the stakeholder ecosystem for access success
  • Step by step: Setting up a cross-functional program for access success
  • Assessment of financial benefit from tendering
  • Evaluating its impact on prices and market concentration
  • Consideration of its operational framework
  • Tendering for pharmaceuticals as a reimbursement tool
  • The importance of making MA the core of the company
  • Bridge between pre-launch strategy and post-launch
  • International Drug Price Indicator Guide WHO
  • Increasing collaboration between countries
  • Frontiers in Health Care
  • What will the future bring?

Newsletter Sign Up

No Spam - You will only receive relevant information on  Real World Evidence, Market Access, Pricing & Reimbursement, and events updates. 

Available Tickets & Discounts

Testimonials

Thank you for a good experience with the PARADIGM Global Events… very high level, very good Organization, we overpassed our expectatives, we will be pending for another congress related to pharmaceutical and biotech… we learned a lot, and i think that the content of agenda was state of the art, thank you again.
SALVADOR BERRIOS
ERP/ CRM / Product Configurator Manager
The consistently high quality of international faculty was most impressive. It was also obvious that they were carefully chosen not only for their particular expertise but also for their ability to communicate the subject matter to clinical and non-clinical participants alike. As market access consultant for pharma clients of various sizes, I now feel much better prepared to explain the nuances & dynamics involved in bringing their products to market. In addition, I am in a much better position to intelligently advice my clients & help them set realistic expectations
THOMAS MARTIN
Associate Vice President, VCGA - Quintiles
I was impressed with the organization of this event. I attend many conferences per year and find the organizers on site to be detached and not focus on good service to the delegates. This team was even providing weather forecast warning to ensure everyone was aware and made appropriate plans. Well Done.
ADRIANA E. MANZI
PhD, Managing Director, Atheln, Inc

Previous events

Register now!

Take Advantage of the Super Early Bird Discount. Group Discounts Also Available. 

sponsors & Exhibitors

Location

Scroll to Top